United States Preventive Services Task Force recommendation statement, Ann. Intern. Med. 157 (2012) 120–134. [2.9] UNITED STATES [2.10] ANDRIOLE, G.L., et al., Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality results after 13 years of follow-up, J. Natl Cancer Inst. 104 (2012) 125–132. [2.11] DRAISMA, G., et al., Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer, J. Natl Cancer Inst. 95 12 (2003) 868–878. [2.12] HUGOSSON, J., et al., Mortality results from the Göteborg randomised population-based prostate-cancer screening trial, Lancet Oncol. 11 (2010) 725–732. [2.13] WILT, T.J., et al., Radical prostatectomy versus observation for localized prostate cancer, N. Engl. J. Med. 367 (2012) 203–213. [2.14] BILL-AXELSON, A., HOLMBERG, L., Radical prostatectomy versus watchful waiting (update), N. Engl. J. Med. 352 (2005) 1977–1984. [2.15] CIEZKI, J., et al., Long-term toxicity and associated cost of initial treatment and subsequent toxicity-related intervention for patients treated with prostatectomy, external beam radiotherapy, or brachytherapy: A SEER/Medicare database study, J. Clin. Oncol. 30 Suppl. 5 (2012). [2.16] SHEETS, N.C., et al., Comparative effectiveness of intensity modulated radiation therapy (IMRT), proton therapy (PT), and conformal radiation therapy (CRT) in the treatment of localized prostate cancer, J. Clin. Oncol. 30 Suppl. 5 (2012). [2.17] WARDE, P., et al., Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial, Lancet 378 (2011) 2104–2111. [2.18] SAUER, R., et al., Preoperative versus post-operative chemoradiotherapy for rectal cancer, N. Engl. J. Med. 351 (2004) 1731–1740. [2.19] SAUER, R., et al., Preoperative versus post-operative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years, J. Clin. Oncol. 30 16 (2012) 1926–1933. 42 [2.20] MINSKY, B.D., INT 0123 (Radiation Therapy Oncology Group 94-05), Phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy, J. Clin. Oncol. 20 5 (2002) 1167–1174. [2.21] ROSENBLATT, E., et al., Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: A prospective multi-centre randomized trial of the International Atomic Energy Agency, Radiother. Oncol. 97 3 (2010) 488–494. [2.22] VAN HAGEN, P., et al., Pre-operative chemoradiotherapy for esophageal or junctional cancer, N. Engl. J. Med. 366 (2012) 2074–2084. [2.23] MORRIS, M., et al., Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer, N. Engl. J. Med. 340 15 (1999) 1137–1143. [2.24] INTERNATIONAL ATOMIC ENERGY AGENCY, Management of Cervical Cancer: Strategies for Limited-resource Centres: A Guide for Radiation Oncologists, IAEA Human Health Reports Series No. 6, IAEA, Vienna (2013). [2.25] McARDLE, O., KIGULA-MUGAMBE, J.B., Contraindications to cisplatin based chemoradiotherapy in the treatment of cervical cancer in Sub-Saharan Africa, Radiother. Oncol. 83 1 (2007) 94–96. [2.26] MAHANTSHETTY, U., et al., Chemoradiation in advanced stage carcinoma cervix: A Phase III randomized trial. Results of 1st interim analysis, Radiother. Oncol. 103 Suppl. 1 (2012) S48–S49. [2.27] CREUTZBERG, C.L., et al., Surgery and post-operative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial, PORTEC Study Group, Post-operative Radiation Therapy in Endometrial Carcinoma, Lancet 355 9213 (2000) 1404–1411. [2.28] NOUT, R.A., et al., Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: First results of the randomized PORTEC-2 trial, J. Clin. Oncol. 27 (2009) 3547–3556. [2.29] NOUT, R.A., et al., Vaginal